TickerFiles

Anika Therapeutics, Inc.

Nasdaq · CIK 0000898437 · Fiscal year end 1231

ANIK

Latest reported period: Latest published period

Revenue

$62.2M

Cost Of Revenue

$22.0M

Gross Profit

$40.2M

Recent financials

MetricCurrentPriorChange
Revenue$62.2M--
Cost Of Revenue$22.0M--
Gross Profit$40.2M--
Operating Income$-2.5M--
Net Income$-1.7M--
Eps Basic-0.13--
Eps Diluted-0.13--
Cash And Equivalents$38.4M--
Total Assets$183.5M--
Shareholders Equity$137.3M--
Operating Cash Flow$-5.5M--
Capital Expenditures$2.9M--

Latest filings

FormCompanyFiledAccession
10-QAnika Therapeutics, Inc.2026-07-290001171843-26-005012
4Anika Therapeutics, Inc.2026-06-230001193125-26-279545
4Anika Therapeutics, Inc.2026-06-230001193125-26-279542
4Anika Therapeutics, Inc.2026-06-230001193125-26-279541
4Anika Therapeutics, Inc.2026-06-230001193125-26-279539
4Anika Therapeutics, Inc.2026-06-230001193125-26-279535
4Anika Therapeutics, Inc.2026-06-050001193125-26-259520
4Anika Therapeutics, Inc.2026-05-040001193125-26-202704
4Anika Therapeutics, Inc.2026-04-300001193125-26-197887
10-QAnika Therapeutics, Inc.2026-04-300001171843-26-002852
4Anika Therapeutics, Inc.2026-03-170001193125-26-111494
4Anika Therapeutics, Inc.2026-03-170001193125-26-111492
4Anika Therapeutics, Inc.2026-03-170001193125-26-111511
4Anika Therapeutics, Inc.2026-03-170001193125-26-111502
4Anika Therapeutics, Inc.2026-03-110001193125-26-102240
4Anika Therapeutics, Inc.2026-03-110001193125-26-102239
4Anika Therapeutics, Inc.2026-03-110001193125-26-102238
10-KAnika Therapeutics, Inc.2026-03-030001171843-26-001275
10-QAnika Therapeutics, Inc.2025-11-050001171843-25-007032
10-QAnika Therapeutics, Inc.2025-07-300001171843-25-004826